Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATCCNSX:ETINYSEARCA:FPENASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATCAtotech$22.71$21.22$18.06▼$25.94$4.42B0.631.09 million shsN/AETIEnviroleach Technologies$0.00$0.00▼$0.00N/AN/AN/A17,860 shsFPEFirst Trust Preferred Securities and Income ETF$17.87+0.2%$17.57$16.77▼$18.23$5.94B0.471.36 million shs924,847 shsHALOHalozyme Therapeutics$54.05+0.4%$55.49$42.01▼$70.51$6.65B1.151.75 million shs868,065 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATCAtotech0.00%0.00%0.00%0.00%0.00%ETIEnviroleach Technologies0.00%0.00%0.00%0.00%0.00%FPEFirst Trust Preferred Securities and Income ETF0.00%+0.68%+1.53%+3.77%+2.23%HALOHalozyme Therapeutics0.00%+3.52%+0.37%-9.57%+3.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATCAtotechN/AN/AN/AN/AN/AN/AN/AN/AETIEnviroleach TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETFN/AN/AN/AN/AN/AN/AN/AN/AHALOHalozyme Therapeutics4.8219 of 5 stars3.11.00.04.42.02.54.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATCAtotech 0.00N/AN/AN/AETIEnviroleach Technologies 0.00N/AN/AN/AFPEFirst Trust Preferred Securities and Income ETF 0.00N/AN/AN/AHALOHalozyme Therapeutics 2.17Hold$61.9014.52% UpsideCurrent Analyst Ratings BreakdownLatest HALO, ETI, ANO, ATC, and FPE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/14/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.005/13/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/13/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$47.005/7/2025HALOHalozyme TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2025HALOHalozyme TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.004/25/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/21/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$55.00 ➝ $58.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATCAtotech$1.50B2.95$1.15 per share19.72$4.24 per share5.36ETIEnviroleach TechnologiesN/AN/AN/AN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETFN/AN/AN/AN/AN/AN/AHALOHalozyme Therapeutics$1.02B6.56$4.66 per share11.61$2.86 per share18.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATCAtotech$7.50M$0.6137.23∞N/A8.14%20.32%5.25%N/AETIEnviroleach TechnologiesN/AN/A0.00N/AN/AN/AN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETFN/AN/A0.00∞N/AN/AN/AN/AN/AHALOHalozyme Therapeutics$444.09M$3.7614.388.690.3644.76%136.91%26.05%8/5/2025 (Estimated)Latest HALO, ETI, ANO, ATC, and FPE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATCAtotechN/AN/AN/AN/AN/AETIEnviroleach TechnologiesN/AN/AN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETF$1.015.65%N/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATCAtotech1.891.901.45ETIEnviroleach TechnologiesN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETFN/AN/AN/AHALOHalozyme Therapeutics3.138.397.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATCAtotech94.57%ETIEnviroleach TechnologiesN/AFPEFirst Trust Preferred Securities and Income ETFN/AHALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipATCAtotech49.90%ETIEnviroleach TechnologiesN/AFPEFirst Trust Preferred Securities and Income ETFN/AHALOHalozyme Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATCAtotech4,033194.66 million97.53 millionNot OptionableETIEnviroleach Technologies147,000N/AN/ANot OptionableFPEFirst Trust Preferred Securities and Income ETFN/A333.91 millionN/ANot OptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableHALO, ETI, ANO, ATC, and FPE HeadlinesRecent News About These CompaniesMoody Aldrich Partners LLC Has $6.17 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 4 at 6:43 AM | marketbeat.comHALO - Halozyme Therapeutics Inc Valuation - MorningstarJuly 3 at 6:51 PM | morningstar.comMWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-TermJuly 3 at 10:51 AM | zacks.comMeritage Portfolio Management Buys Shares of 101,651 Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 3 at 8:07 AM | marketbeat.comNovem Group Acquires 4,821 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 3 at 6:28 AM | marketbeat.comOppenheimer & Co. Inc. Takes $625,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 1, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of HALO Q1 EarningsJuly 1, 2025 | americanbankingnews.comHalozyme Therapeutics Added to Russell 1000® IndexJune 30, 2025 | prnewswire.comHere's Why Halozyme Therapeutics (HALO) is a Strong Value StockJune 30, 2025 | zacks.comZacks Research Issues Pessimistic Forecast for HALO EarningsJune 30, 2025 | marketbeat.comArtemis Investment Management LLP Purchases Shares of 125,652 Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 28, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Spire Wealth ManagementJune 28, 2025 | marketbeat.comHalozyme Therapeutics Inc (RV7.SG)June 26, 2025 | uk.finance.yahoo.comVictory Diversified Stock Fund Q1 2025 CommentaryJune 26, 2025 | seekingalpha.comEnvestnet Portfolio Solutions Inc. Has $721,000 Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 26, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells $1,059,200.00 in StockJune 25, 2025 | insidertrades.comHelen Torley Sells 20,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockJune 24, 2025 | marketbeat.comRetirement Systems of Alabama Has $24.54 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 21, 2025 | marketbeat.comargenx gets EU nod for Vyvgart subcutaneous injectionJune 20, 2025 | msn.comHalozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)June 20, 2025 | prnewswire.comBoston Trust Walden Corp Cuts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsSoundHound’s AI Growth Story Is Just Getting StartedBy Gabriel Osorio-Mazilli | June 16, 2025View SoundHound’s AI Growth Story Is Just Getting StartedWhy Unity Software May Be the AI Breakout No One Saw ComingBy Gabriel Osorio-Mazilli | June 9, 2025View Why Unity Software May Be the AI Breakout No One Saw ComingTop 5 Stocks for July: Momentum-Driven Picks to Watch NowBy Thomas Hughes | June 30, 2025View Top 5 Stocks for July: Momentum-Driven Picks to Watch NowHALO, ETI, ANO, ATC, and FPE Company DescriptionsAtotech NYSE:ATCAtotech Limited, a chemicals technology company, provides specialty electroplating and surface finishing solutions worldwide. The company operates through two segments, Electronics (EL) and General Metal Finishing (GMF). The EL segment manufactures and supplies chemistry, production equipment, software, and services to the electronics industry, which include printed circuit board manufacturers, package substrate makers, and semiconductor companies. Its products and technologies serve the principal electronics end-markets, including communication, computer, automotive, industrial, medical, aerospace, and military industries. The GMF segment provides chemistry, production technology, and services to the surface finishing industries in various areas of application. Its products and technologies serve the primary surface finishing end-markets comprising the automotive, consumer electronics, construction, sanitary, white goods, and oil and gas industries. The company also offers on-site support and training services. Atotech Limited was founded in 1851 and is headquartered in Berlin, Germany.Enviroleach Technologies CNSX:ETIEnviroMetal Technologies Inc. develops and markets technologies for the extraction of precious and other valuable metals from the mine products and electronic waste in the primary and secondary metal sectors. The company's technologies are used in the electronic waste processing industry to recover gold and other valuable metals from PCBA; and the mining industry for the recovery of gold from of ores and concentrates. It also operates E-waste and mineral processing facility. The company was formerly known as EnviroLeach Technologies Inc. and changed its name to EnviroMetal Technologies Inc. in August 2021. EnviroMetal Technologies Inc. was incorporated in 2016 and is headquartered in Burnaby, Canada.First Trust Preferred Securities and Income ETF NYSEARCA:FPE$17.87 +0.03 (+0.17%) As of 07/3/2025 05:00 PM EasternThe First Trust Preferred Securities and Income ETF (FPE) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is an actively managed fund that attempts to generate income by investing globally in preferred equities and income producing debt across the market cap spectrum. FPE was launched on Feb 12, 2013 and is managed by First Trust.Halozyme Therapeutics NASDAQ:HALO$54.05 +0.21 (+0.39%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$54.05 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
